Nyra health has raised €20m to scale its digital neurotherapy platform for neurological rehabilitation, targeting conditions such as stroke and dementia.

The Series A funding will be used to expand the company’s technology across the DACH region, accelerate its expansion into the US and support a more data-driven approach to neurorehabilitation.

Founded in 2021, Vienna-based nyra health has developed a certified medical device called myReha. Patients use the platform to train speech, cognition, fine motor skills and everyday abilities, supported by AI-driven real-time feedback.

The system analyses pathological speech, meaning speech affected by neurological damage, by assessing pronunciation, word retrieval, sentence structure and meaning. It also tracks reaction times, error patterns and training progress, adapting therapy automatically to a patient’s performance level and fatigue.

The company says neurological conditions including stroke, dementia and traumatic brain injury cost €65bn a year in Germany alone, largely because care often declines after patients are discharged from hospital.

Nyra health says myReha is used in more than 100 rehabilitation clinics and is reimbursed by 28 statutory and private health insurers, giving over 40m insured people access to structured, AI-based home therapy. According to the company, a randomised controlled study found that adding myReha to standard therapy led to greater improvements in language and cognitive function than standard therapy alone.

A companion tool, nyra insights, allows therapists to monitor language development, therapy intensity and progress in real time, adjust programmes and generate documentation automatically. An AI-supported Content Studio creates personalised therapy exercises based on individual performance data.

The funding round was led by Armira Growth, with existing investors Wellington Partners, Crane Venture Partners and EVER Pharma also participating. It follows a €4.5m seed round raised in 2023.

Moritz Schöllauf, chief executive and co-founder of nyra health, said:
“From the outset, our goal was to make our services widely available to those affected. Everyone who needs therapy after a stroke or other neurological disease should have access to effective, individualised care, regardless of where they live or how well their own healthcare system is set up. With this round of financing, we are taking another step in this direction.”

Christian Figge, managing partner at Armira Growth, said:
“Neurological rehabilitation can be made significantly more effective through digital solutions, especially in the area of speech ability. nyra health is considered a category creator with a proprietary AI-based solution that connects inpatient therapy, outpatient aftercare and home use.”

The company is also investing in multimodal AI models for therapeutic interaction and diagnostics as part of a €4.2m funded research project being developed with research universities in the US.

Human liver tissue has been reconstructed in 3D at a cellular level, revealing how cirrhosis alters the organ’s internal structure compared with healthy tissue.

The 3D reconstructions capture the fine-scale microstructure of multiple liver lobes and show how scarring disrupts biological activity inside the organ.

Cirrhosis is extensive scarring of the liver caused by long-term damage from viral infection, metabolic disorders, certain medicines or alcohol misuse.

A healthy liver performs more than 500 essential functions, including detoxification, metabolism, digestion, nutrient storage, blood clotting and immune defence.

Kelly Stevens is professor of bioengineering at the UW School of Medicine and the UW College of Engineering, and a senior author of the research.

She said: “Our field has skimmed over a fact that could prevent this dream from becoming reality: We do not know what complex organs look like at a cellular level.

“We do not yet have the ‘blueprints’ of human organs to feed into bioprinters.

“This oversight is important because decades of studies have shown that the structure of human organs, particularly the organ-specific topology of its vasculature, is intimately connected to organ function.

“If the maps are not right, the organs produced will not be functional.”

The work was carried out by engineers and physicians at UW Medicine and the University of Washington, who developed what they describe as the Liver Map pipeline.

Tissue samples were taken from patients who had parts of their liver removed during cancer surgery or who underwent liver transplantation, including samples from cirrhotic livers.

The causes of cirrhosis varied across the samples.

Through the reconstructions, the researchers identified several structural changes linked to cirrhosis.

These included disrupted transport of metabolites in the sinusoidal zones of liver lobes, a reduction in specialised cells that help lower toxic ammonia levels, regression of central vein networks, disruption of artery networks and fragmentation of the bile network, which carries the fluid used to digest fats.

Taken together, the findings point to a broader shift in the liver’s vascular network, meaning the system of blood vessels that supports circulation within the organ.

The team also views the work as a step towards developing replacement organs.

Organ bioprinting is an emerging effort to use 3D printers to build living tissue layer by layer from cells and biomaterials to create organs or partial replacements for transplantation.

The researchers highlighted a key limitation.

The current imaging approach cannot yet capture the full depth of a human liver lobule, the hexagonal units that make up the organ, though they expect this to be addressed as the technology advances.

Eye care startup Custom Surgical has raised €3.5m to modernise ophthalmology by turning analogue slit lamps and microscopes into digital data hubs.

Munich-based Custom Surgical was founded in 2018 by mechatronics engineer Federico Acosta and Fernando Benito. It specialises in digitalising slit lamps and surgical microscopes used in everyday eye care. Slit lamps are standard devices eye doctors use to examine the front and back of the eye using a bright light and magnification.

Rather than replacing existing equipment, the company retrofits devices already in use. Its hardware-agnostic solutions allow clinics and hospitals to capture high-quality images and video without disrupting established workflows.

At the centre of the system is MicroREC Connect, a cloud-based platform that manages ophthalmic data across devices and manufacturers. It enables secure capture, storage and structured organisation of images and video, supporting long-term patient documentation and collaboration between clinical teams.

The company’s strategy follows a phased approach, starting with digitisation, then workflow standardisation, followed by AI-powered clinical support tools. Within the next 12 months, Custom Surgical plans to release its first AI-powered triage tool to help ease waiting times for eye care treatment.

The funding round was a pre-series A and brings the company’s total funding to date to €6m. Custom Surgical said it generated more sales than it raised during this financing round and has reinvested revenue into advancing its product portfolio.

Federico Acosta, chief executive of Custom Surgical, said: “Global demand for eye care is growing at a pace that current clinical processes can no longer sustain. Scalable digital workflows are essential to enable fast, accurate screening for a growing and ageing worldwide population. This financing validates our long-term vision: build the data foundation first, then unlock AI-driven clinical and economic value. We are proud to partner with Ventech, ZEISS, and our investors as we scale globally.”

The round was led by Ventech, with participation from ZEISS and a mix of new and existing investors.

Nicolas Barthalon, principal at Ventech, said: “By uniting hardware, software, data and AI, Custom Surgical is seizing a generational opportunity to reshape clinical eye care workflows at global scale. The team has built a truly unique data asset, achieved global adoption with remarkable capital efficiency, and is addressing a structural inefficiency in a rapidly growing market. We are glad to join forces with industry leaders like Zeiss to fuel Custom Surgical’s ambition to become the data standard in ophthalmology.”

Custom Surgical employs 16 people from nine countries and plans to expand its commercial and engineering teams as it grows across Europe and the US.